{"id":417718,"date":"2021-01-20T08:33:16","date_gmt":"2021-01-20T13:33:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=417718"},"modified":"2021-01-20T08:33:16","modified_gmt":"2021-01-20T13:33:16","slug":"myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/","title":{"rendered":"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BASEL, Switzerland, Jan.  20, 2021  (GLOBE NEWSWIRE) &#8212; Myovant Sciences (NYSE:\u00a0MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc. (MSI) as its chief executive officer, which consisted of restricted stock units (RSUs) to acquire 223,076 common shares of Myovant Sciences Ltd. (Myovant), and an option to purchase 306,427 Myovant common shares. In addition, Myovant granted RSUs to acquire an aggregate of up to 87,300 Myovant common shares to eight other new employees joining MSI. The equity awards were granted to Mr. Marek and the other employees on January 15, 2021 under the 2020 Inducement Plan in accordance with NYSE\u2019s Listed Company Manual Rule 303A.08.<\/p>\n<p>One-fourth of the shares underlying of Mr. Marek\u2019s and other employees\u2019 RSUs will vest on the one-year anniversary of the grant date, with the balance of the common shares vesting in twelve equal quarterly installments thereafter, in each case, subject to each applicable person\u2019s continued employment with Myovant or one of its subsidiaries on such vesting dates. One-fourth of the shares underlying Mr. Marek\u2019s option will vest on the one-year anniversary of the grant date, with the balance of the common shares vesting in twelve equal quarterly installments thereafter, in each case, subject to his continued employment with Myovant or one of its subsidiaries on such vesting dates. The option has an exercise price of $20.54, the closing price of a Myovant common share on the date of grant. The equity awards are subject to the terms and conditions of the 2020 Inducement Plan and the applicable equity award agreements.<\/p>\n<p>\n        <strong>About\u00a0Myovant Sciences\u00a0<\/strong><br \/>\n        <br \/>Myovant Sciences\u00a0aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX\u2122\u00a0for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in\u00a0Europe\u00a0and the\u00a0U.S.\u00a0for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction.\u00a0Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7qQrV3nRWO9lIwKzfL6sqX4kGvDxBXvL2lGUhnJO5vumyyF5OCqAaGh-f1NlIYLaGQywlzfYdmSpAyRrmFaphw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.myovant.com<\/a>. Follow\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4z969024qVwAJZ0F-pGkWzqHilM9Nnijc5FNDqmG_Qyj-23PypNE4mWdCvLzqmt5BhTL8f5ApcPqOtcD4Ez0kg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">@Myovant<\/a>\u00a0on Twitter and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3rnu9rmufg05hYxIv2e4QEWkwmenhsr6yv11KIfBPOjgc5yaVkk-7JVAcZx_0A3OgiB6MMHappeWiCpGLeI3YfTCLgIs3WE4vbtSJxus5tM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>Ryan Crowe<br \/>Vice President, Investor Relations<br \/>Myovant Sciences, Inc.<br \/>+1 (650) 781-9106<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n1QGDGzXR2ZC8u7lSgTml2pVznEruVcSzIXbVDAFrHewk4BMP6dlVeGmjnAsX6PsskNyDnSRhCq7SLwgAHn3GB_RDwyQ8BSt_nzaw3fZYYk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@myovant.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Albert Liao<br \/>Director, Corporate Communications<br \/>Myovant Sciences, Inc.<br \/>+1 (650) 410-3055<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yJC_dA_VEU_WM2QAdBTjTN1ld2zsujJaeqxfpWsH8eSiC19WlCMwv3cM4Mk2pgZ3BE390I3pgXHB4Vzho6-Z_Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@myovant.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/56952975-7b20-48c3-b595-32e61db6d51e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) &#8212; Myovant Sciences (NYSE:\u00a0MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc. (MSI) as its chief executive officer, which consisted of restricted stock units (RSUs) to acquire 223,076 common shares of Myovant Sciences Ltd. (Myovant), and an option to purchase 306,427 Myovant common shares. In addition, Myovant granted RSUs to acquire an aggregate of up to 87,300 Myovant common shares to eight other new employees joining MSI. The equity awards were granted to Mr. Marek and the other employees on January 15, 2021 under the 2020 Inducement Plan in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-417718","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) &#8212; Myovant Sciences (NYSE:\u00a0MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc. (MSI) as its chief executive officer, which consisted of restricted stock units (RSUs) to acquire 223,076 common shares of Myovant Sciences Ltd. (Myovant), and an option to purchase 306,427 Myovant common shares. In addition, Myovant granted RSUs to acquire an aggregate of up to 87,300 Myovant common shares to eight other new employees joining MSI. The equity awards were granted to Mr. Marek and the other employees on January 15, 2021 under the 2020 Inducement Plan in &hellip; Continue reading &quot;Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-20T13:33:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08\",\"datePublished\":\"2021-01-20T13:33:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/\"},\"wordCount\":449,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/\",\"name\":\"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=\",\"datePublished\":\"2021-01-20T13:33:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/","og_locale":"en_US","og_type":"article","og_title":"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk","og_description":"BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) &#8212; Myovant Sciences (NYSE:\u00a0MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc. (MSI) as its chief executive officer, which consisted of restricted stock units (RSUs) to acquire 223,076 common shares of Myovant Sciences Ltd. (Myovant), and an option to purchase 306,427 Myovant common shares. In addition, Myovant granted RSUs to acquire an aggregate of up to 87,300 Myovant common shares to eight other new employees joining MSI. The equity awards were granted to Mr. Marek and the other employees on January 15, 2021 under the 2020 Inducement Plan in &hellip; Continue reading \"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-20T13:33:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08","datePublished":"2021-01-20T13:33:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/"},"wordCount":449,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/","name":"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=","datePublished":"2021-01-20T13:33:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODQ1MSMzOTM1OTYyIzIxNzcyNDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-announces-new-employment-inducement-grants-under-nyse-rule-303a-08-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=417718"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417718\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=417718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=417718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=417718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}